Pages that link to "Q42931947"
Jump to navigation
Jump to search
The following pages link to A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin (Q42931947):
Displaying 50 items.
- Amixicile, a novel inhibitor of pyruvate: ferredoxin oxidoreductase, shows efficacy against Clostridium difficile in a mouse infection model (Q24616179) (← links)
- Ridinilazole: a novel therapy for Clostridium difficile infection (Q26747248) (← links)
- Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection (Q26767079) (← links)
- Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection (Q26770175) (← links)
- Clostridium difficile in the ICU: the struggle continues (Q26823000) (← links)
- The potential for emerging therapeutic options for Clostridium difficile infection (Q28082059) (← links)
- Antimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile Infection (Q28084026) (← links)
- Clostridium difficile infection: New insights into therapeutic options (Q30252154) (← links)
- Treatment of Clostridium difficile infection using SQ641, a capuramycin analogue, increases post-treatment survival and improves clinical measures of disease in a murine model (Q30277636) (← links)
- Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice (Q30417830) (← links)
- Adenosine A2A receptor activation reduces recurrence and mortality from Clostridium difficile infection in mice following vancomycin treatment (Q30423298) (← links)
- Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. (Q30425705) (← links)
- Clostridium difficile infection in older adults (Q33771594) (← links)
- Epidemiology of Clostridium difficile infection (Q34027474) (← links)
- Novel riboswitch-binding flavin analog that protects mice against Clostridium difficile infection without inhibiting cecal flora (Q34044442) (← links)
- Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection (Q34331045) (← links)
- Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice (Q34468946) (← links)
- Novel Fidaxomicin Treatment Regimens for Patients With Multiple Clostridium difficile Infection Recurrences That Are Refractory to Standard Therapies (Q34801881) (← links)
- Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review. (Q35044119) (← links)
- Clostridium difficile in the Long-Term Care Facility: Prevention and Management (Q35065783) (← links)
- The Enteric Two-Step: nutritional strategies of bacterial pathogens within the gut (Q35144567) (← links)
- Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections (Q35164536) (← links)
- Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile (Q35191412) (← links)
- Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile (Q35199072) (← links)
- Microbial bile acid metabolic clusters: the bouncers at the bar. (Q35530701) (← links)
- Effect of fiber supplementation on the microbiota in critically ill patients (Q35619442) (← links)
- In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species (Q35806432) (← links)
- Novel approaches to treating Clostridium difficile-associated colitis. (Q35862915) (← links)
- Fidaxomicin--the new drug for Clostridium difficile infection (Q35877773) (← links)
- How to Manipulate the Microbiota: Fecal Microbiota Transplantation (Q36012805) (← links)
- Clostridium difficile infection: toxins and non-toxin virulence factors, and their contributions to disease establishment and host response (Q36019350) (← links)
- Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection (Q36071501) (← links)
- Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. (Q36071504) (← links)
- Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin (Q36071524) (← links)
- Cost-Effectiveness Analysis of Five Competing Strategies for the Management of Multiple Recurrent Community-Onset Clostridium difficile Infection in France (Q36253963) (← links)
- Toward an understanding of changes in diversity associated with fecal microbiome transplantation based on 16S rRNA gene deep sequencing (Q36351477) (← links)
- Effect of Surotomycin, a Novel Cyclic Lipopeptide Antibiotic, on Intestinal Colonization with Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice (Q36933317) (← links)
- Emerging therapies for Clostridium difficile infection - focus on fidaxomicin (Q36984883) (← links)
- Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes (Q36996876) (← links)
- Effect of Fidaxomicin versus Vancomycin on Susceptibility to Intestinal Colonization with Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice (Q37023290) (← links)
- Fidaxomicin versus conventional antimicrobial therapy in 59 recipients of solid organ and hematopoietic stem cell transplantation with Clostridium difficile-associated diarrhea (Q37124032) (← links)
- Clostridium difficile infection in the twenty-first century (Q37289567) (← links)
- Short- and long-term effects of oral vancomycin on the human intestinal microbiota (Q37509525) (← links)
- Diarylacylhydrazones: Clostridium-selective antibacterials with activity against stationary-phase cells (Q37550108) (← links)
- Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance (Q37588248) (← links)
- Clinical update for the diagnosis and treatment of Clostridium difficile infection (Q37633859) (← links)
- RNA-stable-isotope probing shows utilization of carbon from inulin by specific bacterial populations in the rat large bowel. (Q37712854) (← links)
- Clostridium difficile infection in 2010: advances in pathogenesis, diagnosis and management of CDI. (Q37835698) (← links)
- Treatment of refractory and recurrent Clostridium difficile infection (Q37866629) (← links)
- Fidaxomicin: first-in-class macrocyclic antibiotic (Q37910246) (← links)